Tumor Marker CYFRA 21-1 in NSCLC Patients (16 Months Folow up Study) (CROSBI ID 474782)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Pavićević, Radomir ; Bialk, Petra ; Miličić, Jasna ; Bubanović, Gordana ; Bobić, Jasminka ; Pavićević, Lukrecija
engleski
Tumor Marker CYFRA 21-1 in NSCLC Patients (16 Months Folow up Study)
The serum level of CYFRA21-1 tumor marker has been longitudinally followed in 274 patients with NSCLC lung cancer after the surgery and chemotherapy, five times during 16 months (before the therapy, 1, 4, 10 and 16 months after the therapy. In 240 surgically treated patients the level of tumor marker CYFRA21-1 within 1 to 3 months fell down to the level oh healthy population, i.e. 0.3 to 2.5 ng/mL. The increase of serum level of CYFRA 21-1 was observed 3 months after surgery in 7 patients (6 M, 1 F), that underwent palliative resection. In 26 operated patients during longitudinal follow up noticed the increase of the serum level of CYFRA 21-1 tumor marker 1 to 3 months before other methods proved the relapse of the disease. In 20 patients the increase of the level of tumor marker CYFRA21-1was found at the same time when the relapse of the disease was objectivized with the usual clinical methods. In 6 patients with long distance metastases (Brain, Liver), without local relapse, the level of tumor marker CYFRA 21-1 did not increase. Out of 34 patients who were treated only with the chemotherapy in 20 the level of tumor marker CYFRA 21-1 fell down, in 9 the values increased and in 5 the results were the same as before the applied therapy. According to this results we can conclude that the follow up of tumor marker CYFRA21-1 in every patient after the therapy is very important, because the increase of its concentration show possible local relapse of the disease earlier than using other diagnostic methods. Follow up analysis of tumor marker CYFRA 21-1 in patients who were treated with the chemotherapy show that in 31% patients chemotherapy could not decrease the disease locally. We can also conclude that tumor marker CYFRA 21-1 is necessary in postoperative monitoring in patients with NSCLC, because the increase of its level is a good sign to detect relapse. This is the first part of three-year longitudinal study
tumor marker; CYFRA 21-1; NSCLC; anthropology; population genetics
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
111-111-x.
2000.
objavljeno
Podaci o matičnoj publikaciji
1st Alps Adria Meeting on Human Genetics
Stavljenić Rukavina, Ana
Zagreb: Hrvatsko društvo za humanu genetiku
Podaci o skupu
1st Alps Adria Meeting on human genetics
poster
14.04.2000-15.04.2000
Brijuni, Hrvatska